8-K: Zimmer Biomet to Acquire Paragon 28 in $1.3 Billion Deal

Zimmer Biomet has agreed to acquire Paragon 28 for $13 per share in cash plus a contingent value right, marking a significant move in the orthopedic sector.

Summary

• Zimmer Biomet has entered into a definitive agreement to acquire Paragon 28, a company specializing in foot and ankle orthopedic solutions.
• The acquisition will be completed through a merger, with Paragon 28 becoming a wholly-owned subsidiary of Zimmer Biomet.
• Paragon 28 shareholders will receive $13 per share in cash, plus one contingent value right (CVR) per share.
• The CVR entitles shareholders to a potential additional cash payment of up to $1 per CVR, contingent on Paragon 28 achieving certain revenue targets in 2026.
• The maximum potential payment under the CVR is $1 per CVR, payable if Paragon 28's net revenue exceeds $361 million during the period from January 1, 2026, through December 31, 2026.
• If net revenue is less than $346 million during the same period, no payment will be made under the CVR.
• The deal is valued at approximately $1.3 billion, including the potential CVR payment.
• The merger is subject to customary closing conditions, including approval by Paragon 28 shareholders and regulatory approvals.
• The transaction is expected to close by November 28, 2025, with a possible extension to January 28, 2026.

Sentiment

Score: 7

Explanation: The document is generally positive, outlining a strategic acquisition with potential benefits for both companies. The CVR adds a layer of complexity but also provides upside potential. The risks are clearly stated, but the overall tone is optimistic.

Positives

• The acquisition provides Paragon 28 shareholders with an upfront cash payment of $13 per share.
• The CVR offers the potential for additional upside if Paragon 28 meets its 2026 revenue targets.
• The deal is not subject to a financing condition, increasing the certainty of closing.
• Paragon 28's CEO will take a leadership role in the combined company, suggesting a smooth integration.
• The acquisition will expand Zimmer Biomet's presence in the foot and ankle orthopedic market.

Negatives

• The CVR payment is contingent on Paragon 28 achieving specific revenue targets, and there is no guarantee that the full $1 per CVR will be paid.
• The deal includes a $40 million termination fee payable by Paragon 28 under certain circumstances.
• The merger is subject to regulatory approvals and other closing conditions, which could delay or prevent the transaction from closing.
• There is a risk of disruption from the pending merger, which could make it more difficult to maintain business and operational relationships.

Risks

• The merger is subject to regulatory approvals, which may not be obtained or may be delayed.
• There is a risk that competing offers for Paragon 28 could emerge.
• The merger could be terminated if a material adverse effect occurs at Paragon 28.
• The integration of the two businesses may not be successful, and the expected benefits of the merger may not be realized.
• The revenue milestone necessary for the CVR payment may not be achieved.
• The merger could divert management's attention from ongoing business operations.
• The announcement of the merger could negatively affect the market price of Zimmer Biomet's stock.

Future Outlook

The document includes forward-looking statements regarding the expected completion and timing of the proposed transaction, as well as the potential benefits and risks associated with the merger. The CVR payment is contingent on Paragon 28 achieving specific revenue targets in 2026.

Management Comments

• Albert DaCosta, Paragon 28's Chairman, President and Chief Executive Officer, will hold the position of Global President, Foot and Ankle at Zimmer Biomet after the merger.

Industry Context

This acquisition reflects a trend of consolidation in the orthopedic industry, with larger companies seeking to expand their product portfolios and market reach. The focus on foot and ankle solutions highlights a growing area of demand within the orthopedic sector.

Comparison to Industry Standards

• The acquisition of Paragon 28 by Zimmer Biomet is comparable to other recent acquisitions in the medical device industry, where larger companies acquire smaller, specialized firms to expand their product offerings and market share.
• For example, Stryker's acquisition of Wright Medical in 2019 for approximately $5.4 billion is a similar transaction in the orthopedics space, focusing on extremities and biologics.
• The use of a contingent value right (CVR) is also a common feature in such deals, allowing the acquiring company to mitigate risk while providing potential upside to the acquired company's shareholders.
• The $13 per share cash consideration and the potential $1 per share CVR payment are within the range of premiums seen in similar transactions, although the specific value will depend on Paragon 28's future performance.
• The revenue targets set for the CVR are specific to Paragon 28's business and are not directly comparable to other companies, but they reflect a common practice of tying a portion of the acquisition price to future performance.

Management Changes

Legal Proceedings

• The document mentions the risk of litigation, including shareholder litigation, related to the merger.

Stakeholder Impact

• Paragon 28 shareholders will receive cash and a potential CVR payment.
• Paragon 28 employees will become part of Zimmer Biomet, with some changes to their roles and benefits.
• Customers of both companies may see changes in product offerings and services.
• Suppliers and other business partners may be affected by the integration of the two companies.

Next Steps

• Paragon 28 will file a proxy statement with the SEC.
• Paragon 28 shareholders will vote on the merger agreement.
• The parties will seek regulatory approvals.
• The merger is expected to close by November 28, 2025, with a possible extension to January 28, 2026.

Key Dates

Keywords

merger, acquisition, orthopedics, foot and ankle, contingent value right, Zimmer Biomet, Paragon 28, healthcare, medical devices, revenue milestone